Table 3 Significant CYP4F2 variants associated with COPD susceptibility in males
SNP | Model | Genotype | Control | Case | Unadjusted | Adjusted for Gender and Age | ||
|---|---|---|---|---|---|---|---|---|
OR(95%CI) | pa-value | OR(95%CI) | pb-value | |||||
rs3093203 | AA | 17 | 18 | 1 | 1 | |||
Codominant | AG | 124 | 93 | 1.43 (1.00–2.04) | 0.052 | 1.04 (0.64–1.68) | 0.881 | |
GG | 196 | 103 | 2.02 (1.00–4.08) | 0.051 | 1.13 (0.42–3.03) | 0.804 | ||
Dominant | AA | 141 | 111 | 1 | 1 | |||
AG-GG | 196 | 103 | 1.50 (1.06–2.11) | 0.022 | 1.05 (0.66–1.66) | 0.838 | ||
Recessive | AA-AG | 17 | 18 | 1 | 1 | |||
GG | 320 | 196 | 1.73 (0.87–3.43) | 0.118 | 1.12 (0.43–2.92) | 0.825 | ||
Log-additive | – | – | – | 1.42 (1.08–1.88) | 0.013 | 1.05 (0.72–1.53) | 0.799 | |
rs3093193 | GG | 18 | 6 | 1 | 1 | |||
Codominant | GC | 141 | 88 | 0.77 (0.54–1.08) | 0.133 | 1.08 (0.68–1.70) | 0.756 | |
CC | 177 | 144 | 0.41 (0.16–1.06) | 0.066 | 0.61 (0.18–2.09) | 0.435 | ||
Dominant | GG | 159 | 94 | 1 | 1 | |||
GC-CC | 177 | 144 | 0.73 (0.52–1.02) | 0.063 | 1.03 (0.66–1.6) | 0.907 | ||
Recessive | GG-GC | 18 | 6 | 1 | 1 | |||
CC | 318 | 232 | 0.46 (0.18–1.17) | 0.102 | 0.60 (0.18–1.99) | 0.399 | ||
Log-additive | – | – | – | 0.72 (0.54–0.97) | 0.030 | 0.96 (0.65–1.42) | 0.852 | |
rs3093110 | GG | 4 | 0 | 1 | 1 | |||
Codominant | GA | 67 | 24 | 0.45 (0.27–0.73) | 0.002 | 0.39 (0.20–0.76) | 0.005 | |
AA | 265 | 213 | – | – | – | – | ||
Dominant | GG | 71 | 24 | 1 | 1 | |||
GA-AA | 265 | 213 | 0.42 (0.26–0.69) | 0.001 | 0.38 (0.19–0.73) | 0.004 | ||
Recessive | GG-GA | 4 | 0 | 1 | 1 | |||
AA | 332 | 237 | – | – | – | – | ||
Log-additive | – | – | – | 0.42 (0.26–0.68) | p < 0.000 | 0.38 (0.20–0.73) | 0.004 | |